CDK4 and melanoma: Additionally, the potential therapeutic value of MEK inhibitors combined with inhibition of downstream effectors (MAPK, PI3K, or CDK4/6) or upstream effectors (RTK, STK19) for melanomas with NRAS mutations has been demonstrated, but the choice remains controversial [71].